Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Net Income of $263.86 million for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $263.86M | +396.9% |
| 2024 | -$88.88M | +60.8% |
| 2023 | -$226.54M | +8.3% |
| 2022 | -$247.12M | -34.3% |
| 2021 | -$184.06M | -0.7% |
| 2020 | -$182.81M | -67.9% |
| 2019 | -$108.90M | -7.6% |
| 2018 | -$101.25M | -53.9% |
| 2017 | -$65.78M | -19.3% |
| 2016 | -$55.14M | -28.2% |
| 2015 | -$43.02M | +4.8% |
| 2014 | -$45.19M | -50.1% |
| 2013 | -$30.11M | +23.0% |
| 2012 | -$39.08M | +31.4% |
| 2011 | -$56.95M | -68.2% |
| 2010 | -$33.85M | -151.7% |
| 2009 | -$13.45M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.90M | +191.9% | +153.7% |
| June 30, 2025 | $5.08M | +140.1% | +15790.6% |
| March 31, 2025 | $32.0K | +100.1% | +100.2% |
| September 30, 2024 | -$14.03M | +61.2% | -10.7% |
| June 30, 2024 | -$12.67M | +83.2% | +64.2% |
| March 31, 2024 | -$35.38M | +33.7% | +2.1% |
| September 30, 2023 | -$36.15M | +15.0% | +52.0% |
| June 30, 2023 | -$75.33M | -28.0% | -41.2% |
- BIOCRYST PHARMACEUTICALS INC showed an increase of +396.9% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, BIOCRYST PHARMACEUTICALS INC’s net income has grown by 2061.6% (from -$13.45 million to $263.86 million).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: